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Abstract 
In this research paper the cost of overweight and obesity in Estonia is studied. 
Prevalence based top-down cost-of-illness method and Estonian Health Insurance cost 
data for healthcare services and medications of 11 diseases associated with excess body 
weight is used. The results show the economic burden of overweight and obesity in 
2015 was €45,5 million (0,22% of GDP, 3,7% of healthcare expenditures). While the 
cost of overweight and obesity is not yet as large as in other European countries or the 
USA, it is still a serious warning sign from the viewpoint of public health. To alleviate 
the problem, taxes on unhealthy food and drink products and taxes based on body 
weight are proposed. 
Keywords: obesity, overweight, cost-of-illness, healthcare expenditures, health 
economics 
 
1. Introduction 
Overweight and obesity have become popular topics in public debate and health policy 
in the last couple of decades. There can be many definitions of overweight and obesity; 
of the five anthropometric indices for diagnosing obesity – body mass index (BMI), 
body fat percentage, waist circumference, waist-to-hip ratio and waist-to-stature ratio – 
the most commonly used index around the world, including World Health Organisation 
(WHO), is BMI (Cheng 2004). BMI shows the relationship between weight (in 
kilograms) and height (in meters) and is calculated as follows: 
(1)    !"# =!"#$ℎ! ∙ !"#$ℎ! !! 
A person is considered overweight if BMI ≥ 25 and obese if BMI ≥ 30. Obesity is 
divided into 3 classes: 
• moderate (class I) obesity: 30 ≤ BMI < 35, 
• severe (class II) obesity: 35 ≤ BMI < 40, 
• morbid (class III) obesity: BMI ≥ 40. 
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It is an important fact that worldwide obesity has more than doubled since 1980. In 
2014, more than 1,9 billion adults (39%) worldwide were overweight, of these over 600 
million (13%) were obese. Globally more people live in countries where overweight 
(including obesity) kills more people than underweight. (Obesity and overweight) It is 
clear overweight and obesity are spreading fast globally and show no signs of retreat 
(see graph 1). 
 
Graph 1. Proportion of overweight (BMI ≥ 25) people in selected countries in 2014 
(WHO database; compiled by the author) 
In the recent years the topic of overweight and obesity has been discussed more and 
more also in Estonia. In 2014, 60,3% of adults in Estonia was overweight and 24,5% 
was obese (WHO database). These numbers show obesity is definitely a topical issue in 
Estonia. The same conclusion can also be drawn from the fact that overweight and 
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obesity have been addressed on a governmental level, for example by Republic of 
Estonia Ministry of Social Affairs in 'The National Health Plan 2009–2020' [in 
Estonian: 'Rahvastiku Tervise Arengukava 2009–2020'] (National Health…) and by 
official nutritional guidelines, healthy eating and recreational sports campaigns from 
National Institute of Health Development [NIHD, in Estonian: Tervise Arengu Instituut] 
(National Institute of…). It is clear the government is starting to sense the importance of 
this health issue and has already taken some measures to alleviate it. However, the 
author of this research believes more serious actions should be taken, considering how 
costly overweight and obesity can actually become. Unlike many other medical 
conditions like cancer, neurodegenerative diseases (for example Parkinson's, 
Alzheimer's, Huntington's disease) and genetic disorders (for example Down syndrome), 
overweight and obesity are a great deal more preventable and curable, therefore making 
it possible to reduce the related costs by a significant amount. 
In order to alleviate the problem, it is important to find possible causes. At the most 
basic level, the cause of increased body weight is well understood: individuals gain 
weight when calories consumed exceed those expended. (Finkelstein et al 2005) So it 
comes down to either consuming too much calories or expending too little of consumed 
calories or both simultaneously. Globally, there has been an increased intake of energy-
dense fatty foods and a decrease in physical activity as a result of the increasingly 
sedentary nature of many forms of work, changing modes of transportation and 
increasing urbanization. So, in order to reduce overweight and obesity and associated 
costs, it is important to normalize energy intake, increase fruit and vegetable intake and 
engage in physical activities regularly (2,5 hours per week) according to WHO. As 
WHO emphasizes, individual responsibility can only have its full effect if people have 
access to a healthy lifestyle. Therefore, at the societal level it is important to support 
individuals through sustained political commitment and the collaboration of many 
public and private stakeholders and make regular physical activity and healthier dietary 
choices available, affordable and easily accessible to all, especially the poorest 
individuals. (Obesity and overweight) 
As already mentioned, overweight and obesity do not come without costs. There are 
both direct and indirect costs. (Hammond and Levine 2010, Lehnert et al 2013) The 
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direct costs come first and foremost from obesity-related medical spending since 
excessive weight is linked with many diseases, for example type 2 diabetes, 
hypertension, hypercholesterolemia, coronary heart disease (CHD) and stroke but also 
with asthma, arthritis, depression, some types of cancer, infertility and pregnancy issues, 
gout, hyperinsulinaemia, kidney disease, sleep apnoea, depression and many others 
(Hammond and Levine 2010, Finer 2006, Obesity and overweight, Kortt et al 1998). 
Diagnosis and treatment of these conditions come with great expenditures. Direct costs 
come also from non-medical spending, for example costs related to visiting the doctor 
or a hospital, i.e. transportation, food, lodging (Wolf and Colditz 1998), costs to change 
diet, car, housing and costs related to taking up sports (Segel 2006). The indirect costs 
include mostly productivity costs: increased absenteeism, presenteeism, disability and 
premature mortality (Hammond and Levine 2010, Lehnert et al 2013, Grossel et al 2004, 
Fontaine et al 2003), and decreased human capital accumulation: decreased years of 
schooling (Gortmaker et al 1993) and school attendance (Geier et al 2007) and weaker 
academic performance (Sabia 2007). There can be other indirect costs as well, for 
example increased disability benefit payments (Burkhauser and Cawley 2010), health 
insurance market externalities (Bhattacharya and Sood 2010), fuel (Dannenberg et al 
2004, Jacobson and King 2009) and environmental costs (Michaelowa and Dransfield 
2006).  
Many authors have tried to estimate the cost of (overweight and) obesity. Most of the 
studies include only direct medical costs; there are only a few also incorporating 
indirect productivity costs. Not much has been published about the cost of obesity on a 
global level. Dobbs et al (2014) have been among the very few to do so. They found the 
global economic impact from obesity is roughly $2 trillion or 2,8% of global GDP, 
roughly equivalent to the global impact from smoking or armed violence, war and 
terrorism. The healthcare toll of obesity can reach up to 20% of health expenditures in 
developed countries. As can be assumed, the greatest share of research focuses on the 
USA. Wolf and Colditz (1998) found total cost of obesity in 1995 was $99 billion 
(10,9% of total health expenditures, 1,44% of GDP). Finkelstein et al (2003) estimated 
direct cost of obesity to $78 billion (9,1% of health expenditures, 1,26% of GDP) in 
1998. According to the same authors, the cost had almost doubled in 10 years in 
absolute terms: it was 147 billion (10% of health expenditures or 1,13% of GDP) 
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(Finkelstein et al 2009). However, Cawley and Meyerhoefer (2012) found direct 
medical cost of obesity in 2008 was even larger: $210 billion (20,6% of health 
expenditures, 1,61% of GDP). This discrepancy comes first and foremost from the use 
of different methods. 
The aim of this paper is to evaluate cost of overweight and obesity in Estonia in 
monetary terms. The author will also provide some suggestions and policy proposals to 
reduce the estimated costs, for example via tax policy that typically has not been 
included in cost of obesity studies. There is a clear research gap: cost of obesity 
research has been conducted and published for many other countries (USA, UK, 
Australia, Canada, New Zealand, the Netherlands, France, Sweden, Germany, China, 
Thailand, Mexico etc) by many authors using various methods but never before for 
Estonia, a small post-Soviet eastern European country with relatively poor health 
indicators and relatively low healthcare expenditures: 6,2% of GDP in 2014 (NIHD 
database, for comparison with other countries see appendix 3). This sort of cost 
evaluation provides valuable information for public health practitioners to argue for 
more prevention resources, for policy makers to allocate resources inside the healthcare 
system, give insight to how much could be saved through successful prevention and 
provide important information for cost-effectiveness and cost-benefit analyses.  
To study the cost of overweight and obesity in Estonia, prevalence based top-down 
cost-of-illness (COI) method and Estonian Health Insurance cost data for healthcare 
services and medications of 11 diseases associated with excess body weight is used. The 
diseases were divided into five categories: cancers, endocrine diseases, cardiovascular 
diseases, digestive diseases and musculoskeletal disorders. The economic burden of 
overweight and obesity in 2015 was €45,5 million (0,22% of GDP, 3,7% of healthcare 
expenditures). The most costly disease categories were cardiovascular (50% of total 
direct costs) and endocrine diseases (38%). From the results it appears overweight and 
obesity is not yet as large of a problem as in other European countries or the USA but it 
is still a serious warning sign from the viewpoint of public health. To alleviate the 
problem, taxes on unhealthy food and drink products and taxes based on body weight 
are proposed. 
 7 
The paper is structured as follows. Section 2 gives a literature review on the topic. 
Section 3 introduces cost-of-illness method and data, followed by section 4 in which 
analysis and main results are presented. Section 5 provides a rather extensive discussion 
and section 6 concludes and summarizes the main findings of the study. 
 
2. Literature Review 
Overweight and obesity have direct and indirect costs. The most important theoretical 
links are presented in graph 2.  
Direct costs 
First of all, the most apparent and researched cost of overweight and obesity is direct 
cost, first and foremost direct medical spending. Excessive weight is linked with higher 
risk of numerous diseases, most importantly and widely known with type 2 diabetes, 
hypertension, hypercholesterolemia, coronary heart disease (CHD) and stroke but also 
with asthma, arthritis, depression, some types of cancer (for example breast cancer, 
cancer of pancreas, colon and uterus), infertility and pregnancy issues, gout, hyper-
insulinaemia, kidney disease, sleep apnoea, depression and many others (Hammond and 
Levine 2010, Finer 2006, Obesity and overweight, Kortt et al 1998, see illustration 1).  
For example, Thompson et al (1999) have estimated the relationship of obesity and five 
most frequently associated diseases (diabetes, hypertension, hypercholesterolemia, 
CHD and stroke). As expected, they found risks of all diseases higher for the obese and 
overweight for both men and women. For example, the risk of hypertension was twice 
as high and risk of diabetes was almost three times as high for the obese compared to 
the healthy weight group. Risks of CHD and stroke did not increase as much with BMI 
but were still roughly 15–20% higher for the obese group. Similar results for diabetes 
and hypertension but also statistically significant increase in risk of hyper-
cholesterolemia, asthma and arthritis have been found in Rimm et al (1995), Gorsky et 
al (1996), Van Itallie (1985) and Mokdad et al (2001). It is clear overweight and obesity 
are serious risk factors to many diseases. 
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Graph 2. Possible costs of overweight and obesity (based on Lehnert et al (2013), amended by the author) 
Cost of overweight 
and obesity 
Direct costs 
Non-medical 
costs 
Costs related to 
doctors' visits 
Changes in diet, 
housing, car 
Sports 
Medical costs 
Doctors' 
appointments 
Hospital costs 
Allied health 
professional costs 
Pharmaceutical & 
laboratory tests 
Medications & 
medical supplies 
Nursing home 
care 
Indirect costs 
Productivity 
costs 
Morbidity 
Absenteeism 
Presenteeism 
Disability 
Premature 
mortality 
Human capital 
accumulation 
Years of 
schooling 
School 
attendance 
Academic 
performance 
Other 
Transportation 
costs 
Fuel costs 
Environmental 
costs 
Health insurance 
externality 
Disability 
benefit 
payments 
 9 
 
Illustration 1. Diseases associated with excessive weight (based on Finer (2006), 
amended by the author)  
The diagnosis and treatment of these health problems come with great costs, consisting 
of allied health professional (profession distinct from nursing, medicine and pharmacy, 
for example psychologist, therapist, nutritionist etc) costs, pharmaceutical and 
laboratory test costs, hospital (including emergency department) costs (inpatient and 
outpatient procedures and rehabilitation), general practitioner (medical / family doctor) 
visit costs, medications' and medical supplies' costs, nursing home care costs etc (Lal et 
al 2012, Segel 2006). Since the rise of overweight and obesity will increase incidence of 
these diseases, medical costs will grow with obesity rates. Many studies have tried to 
estimate these costs with variety of methods: cost-of-illness studies, regression analyses, 
simulation forecasting, instrumental variable (IV) approach etc. (Hammond and Levine 
2010) Authors seem to agree obesity-related medical costs are indeed substantial. 
Many authors have studied how excessive weight affects healthcare costs. Thompson et 
al (2001) used a retrospective study with 1286 respondents who were sorted into three 
groups: healthy, overweight and obese according to their initial BMI. Respondents were 
followed for nine years. They found that compared to the healthy weight group, the 
obese had on average 36% and the overweight 10% higher annual medical costs. 
Thorpe et al (2004) carried out a two-part regression controlling for key individual 
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variables like demography, insurance status and smoking. In 1987 the medical costs of 
the obese were 15,2% higher than the costs of the healthy weight but by 2001 the 
difference had already increased to 37%. Finkelstein et al (2003) found the average 
increase in annual medical expenditures associated with obesity was 37,4% in 1998, the 
same result found by Thompson et al (2001) and Thorpe et al (2004). Sturm (2002) did 
a rather interesting comparison study and contrasted healthcare cost of obesity, 
overweight, smoking and excessive drinking. Obesity had roughly the same effect on 
chronic health problems as twenty years’ aging that exceeds the effects of smoking or 
drinking by a great amount. Obesity increased health service costs by 36% and 
medication costs by 77%, compared with being in a normal weight range; twenty years’ 
aging increased service costs 20% and medications costs 105%; current or past smoking 
increased service costs 21% and medications costs 28–30% (see graph 3). The effects of 
excessive drinking and being overweight were not statistically significant. Smoking and 
excessive drinking has received quite a lot of attention in public health policy in the last 
decades, although as appeared from Sturm (2002) study, obesity is associated with a 
larger impact on expenses. 
 
Graph 3. Cost increases associated with obesity, aging, smoking, and drinking in 1998 
(Sturm 2002) 
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Many studies have estimated direct medical costs of obesity (usually defined as BMI ≥ 
30) or overweight and obesity (BMI ≥ 25). Wolf and Colditz (1998) presented results 
for the United States in 1995. They used NHIS (National Health Interview Survey) data, 
cost-of-illness method (including population-attributable risk percents) and generalized 
to whole US population. Since obesity is related with many diseases, they included the 
most important ones in their study: type 2 diabetes, cardiovascular disease, gallbladder 
disease, breast, endometrial and colon cancer and musculoskeletal disease. The direct 
cost attributable to obesity was $52 billion (5,7% of health expenditures, 0,75% of 
GDP). 63% of direct costs were associated with diabetes, 14% with CHD, 8% with 
musculoskeletal disease, 6% with hypertension, 5% with gallbladder disease and 4% 
with mentioned types of cancer. Impact of obesity was similar to complete impact of 
diabetes, 1,25 times larger than impact of CHD, 2,7 times larger than impact of 
hypertension. Excess body weight put a burden of significant size on the healthcare 
system. Also, the authors bring out the cost of excess weight might be underestimated. 
They defined obesity as BMI ≥ 29 but most health risks appear in most diseases already 
at BMI ≥ 25, so the economic toll of overweight could be much larger. Other authors 
have also estimated the cost (overweight and) obesity in the USA (Finkelstein et al 2013, 
Finkelstein et al 2009, Cawley and Meyerhoefer 2012). The cost in absolute values 
varied from $78 billion to $210 billion (9,1% to 20,6% of healthcare expenditures or 
1,13% to 1,61% of GDP) (for a more comprehensive overview see appendix 1) As 
already concluded by Wolf and Colditz (1998), obesity represents a major avoidable 
contribution to the overall cost of illness in the United States.  
But the cost of overweight and obesity has also been studied in other countries. Direct 
medical cost in different countries in various years as a percentage of GDP is 
summarized in graph 4 and later on also in table 1 (based on information from appendix 
1). In European countries, the cost of (overweight and) obesity reached from 0,2% to 
0,4% of GDP. In Australia and New Zealand it was typically slightly higher and varied 
from 0,3% to 0,65% of GDP (excluding Australia 1990 from Segal et al 1994). In 
Canada the corresponding figures reached from 0,26% to 0,4%, being very similar to 
European countries. In less developed countries the cost of overweight and obesity was 
noticeably smaller: 0,06%–0,18% of GDP. This outcome is probably partly due to the 
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fact obesity is not yet as prevail in these countries (see again graph 1) and partly 
because they simply do not expend as much on healthcare. 
 
Graph 4. Direct medical cost of (overweight and) obesity as a percentage of GDP 
(compiled by the author from appendix 1) 
Indirect costs 
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Lehnert et al 2013, Grossel et al 2004, Fontaine et al 2003) There have been very few 
published studies that include productivity losses (in monetary terms) in the cost of 
obesity (Lal et al 2012). 
Studies find strong correlation between higher rates of absenteeism and obesity. For 
example, 3,73 days of work per each obese employee were annually lost in the Northern 
American division of Shell Oil Company compared to normal weight workers. 
Productivity losses due to absenteeism from obesity-related reasons reached 11,2 
million US dollars per year. (Tsai et al 2008) Wolf and Colditz (1998) estimated obesity 
resulted in 239 million restricted activity days and 89,5 million bed days in 1995. 
Tucker and Friedman (1998) reported obese employees (percent body fat ≥ 25% and 
30% for men and women, respectively) are 1,74 and 1,61 times more likely to 
experience high (7 or more absences due to illness per 6 months) and moderate (3–6 
more absences due to illness per 6 months) levels of absenteeism, respectively, than 
their lean counterparts (percent body fat ≤ 15% and 20% for men and women, 
respectively). Trogdon et al (2008) estimated obesity-related productivity losses from 
absenteeism in the United States to range from $3,38 billion to $6,38 billion per year. 
Thompson et al. (1998) estimated obesity-attributable absenteeism cost employers $2,4 
billion in 1998. Ricci and Chee (2005) tried to estimate total lost productivity time 
(LPT), i.e. add cost of presenteeism to cost of absenteeism. They found LPT among 
obese workers in the US reached $11,7 billion per year. Surprisingly, absenteeism 
attributed to only one third and presenteeism to two thirds, so the latter may actually be 
a bigger problem in economic terms. These numbers show a relevant economic cost.  
Most of the studies dealing with costs of (overweight and) obesity have not estimated 
indirect costs but there are a few available (see all empirical cost of overweight and 
obesity studies summarized in appendix 1). In addition to direct medical spending, Wolf 
and Colditz (1998) also estimated productivity costs related with obesity-associated 
diseases, total cost of obesity reached $99 billion in 1995 (10,9% of health expenditures 
or 1,44% of GDP). Colditz (1992) did a very similar study with older data for 1986 
(excluding musculoskeletal disease); the economic cost of obesity then was $39 billion 
(5,5% of health expenditures or 0,49% of GDP). Total cost (direct medical + 
productivity cost) of (overweight and) obesity in different countries in various years as a 
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percentage of GDP is summarized in graph 5 and table 1. In European countries, the 
total cost varied from 0,28% to 0,5% of GDP. In Canada, it was higher: 0,47%–0,73% 
of GDP. In less developed countries, the total cost of (overweight and) obesity was 
again significantly smaller: 0,13%–0,3% of GDP. As already mentioned, due to both 
less prevalence of overweight and smaller overall medical expenditures. 
 
Graph 5. Total cost (direct medical spending + productivity cost) of (overweight and) 
obesity as a percentage of GDP (compiled by the author from appendix 1) 
Table 1. Comparison of cost of (overweight and) obesity as a percentage of GDP by 
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Europe 0,2–0,4% 0,3–0,5% 
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males was found by Kaestner et al (2009). School attendance and obesity were studied 
by Geier et al (2007) who identified days missed from school were higher for obese 
children. Moreover, Sabia (2007) has shown that adolescent obesity has a negative 
effect on grade point average (GPA). These results provide evidence that obesity has a 
negative impact on school attendance, educational attainment, grades and knowledge 
and a positive impact on dropping out of school. Clearly, human capital accumulation 
seems to be negatively affected by obesity, especially childhood and adolescence 
obesity. However, these costs have usually not been estimated due to lack of data and/or 
difficulties with measurement. 
In addition to indirect effects from productivity costs and human capital accumulation, 
there could be other, less significant obesity-related factors affecting the overall costs, 
for example increased disability payments (Burkhauser and Cawley 2010) and welfare 
loss from health insurance market externality (Bhattacharya and Sood 2010). One 
interesting, yet not so widely studied cost is the effect overweight and obesity might 
have on transportation costs, both directly, as more fuel and larger vehicles are needed 
for the same number of commuters (Dannenberg et al 2004, Jacobson and King 2009), 
and indirectly, in the form of greater greenhouse gas emission (Michaelowa and 
Dransfield 2006). Other possible (and perhaps weakly related) factors remain 
unidentified at the moment and need further research.  
Although annual healthcare costs among the obese are higher, it has been occasionally 
mentioned that lifetime costs may be lower because obese individuals live shorter lives 
(Stevens et al 1998, Fontaine et al 2003). However, it has not been confirmed by studies 
conducted (Thompson et al 1999, Allison et al 1999, Gorsky et al 1996), especially if 
indirect costs of overweight and obesity are included. Authors agree obesity-related 
costs comprise a significant proportion of total healthcare expenditures and add to the 
burden of the whole society. 
The case of Estonia 
Overweight and obesity in Estonia are yet to be studied from a monetary perspective. 
There have only been a few authors who have tried to research this topic in Estonia 
from a more economic viewpoint. Vals et al (2013) studied how alcohol consumption, 
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smoking and overweight affect utilization of healthcare services, using binary logistic 
regression and data from Health Behaviour Survey of the Estonian Adult Population. 
They found the odds of visiting a GP (general practitioner / medical / family doctor) 
were almost 80% higher for obese women and 32% higher for obese men and both 
obese men and women had 28% higher odds of visiting a specialist compared to 
respondents whose weight was normal. Obese women also had 54% higher odds for 
hospitalizations and 45% higher risk for ambulance calls. Overall, overweight and 
smoking had the largest impact on healthcare utilization in Estonia. They also 
emphasize that considering the high prevalence of these behavioral risk factors, health 
policies should prioritize preventive programs promoting healthy lifestyles in order to 
decrease the disease burden and to reduce healthcare costs. A study by Tekkel et al 
(2010) also confirms the previous result: obese men and women tend to use outpatient 
services more than normal weight individuals.  
Republic of Estonia Ministry of Social Affairs and University of Tartu Department of 
Public Health (2004) estimated burden of disease in Estonia, measured in years of life 
lost, and connections with risk factors, including overweight. They found 5% of burden 
of disease (approximately 17 000 years of life lost) in Estonia is caused by overweight 
or obesity, respective numbers for alcohol abuse, smoking and drug abuse were 6,7%, 
8,3% and 1%. In comparison to more prioritized problems like smoking and alcohol 
abuse, the damage by obesity is actually not far off. Coronary heart disease caused 53% 
of overweight related mortality, followed by stroke and hypertension. In total these 
three diseases caused 86% of years of life lost associated with overweight.  
From these studies we get some insight that overweight and obesity are topical issues in 
Estonia and create excessive burden on the society. The severity of this issue and the 
size of the burden, however, need further investigation.  
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3. Method and Data 
Health economics deals with allocation of scarce resources to improve health, both 
within the economy to healthcare system and within the healthcare system to different 
activities and individuals. One important field of applied research in health economics is 
cost-of-illness research (COI). COI studies first appeared in 1950s and since then, at 
least 1700 have been published in USA alone (U.S. Health Policy…). Cost-of-illness 
(or burden-of-illness) studies are not concerned with a particular healthcare intervention 
but instead attempt to estimate the economic burden a specific disease places on society. 
(Kobelt 2013) As stated by Rice (2000), cost-of-illness studies translate the adverse 
effects of diseases or injuries into monetary terms, the universal language of decision 
makers and the policy arena. These estimates are used to:  
• define the magnitude of the disease or injury in monetary terms;  
• justify intervention programs;  
• assist in the allocation of research finances on specific diseases;  
• provide a basis for policy and planning relative to prevention and control 
initiatives;  
• provide an economic framework for program evaluation.  
The aim of COI studies is descriptive: it aims to itemize, value and sum the costs of a 
particular problem to give an idea of its economic burden (Jefferson et al 2000). It gives 
insight about the amount of scarce resources consumed because of the illness (Tarricone 
2006). COI studies try to estimate the maximum amount that could potentially be saved 
or gained if a disease were to be eradicated. Also, cost-of-illness studies provide 
important information for cost-effectiveness and cost-benefit analyses. (Segel 2006) 
COI studies give valuable insight for the healthcare system: usually there is no surplus 
in the healthcare budget and more effective use of available resources would benefit 
everyone via the increase of quantity of other healthcare services offered. It is not a 
question of reducing healthcare costs in total or creating surpluses in the healthcare 
budget; it is the question of opportunity cost(s) of treating a particular health problem 
and effective allocation of resources within the healthcare system. 
 
 18 
Costs 
A comprehensive cost-of-illness study includes both direct and indirect costs, although 
the specific focus of a study may make one or the other unnecessary. Some studies also 
include intangible costs of pain and suffering but this category of costs is often omitted 
because of the difficulty in accurately quantifying it in monetary terms. In COI studies, 
direct costs include direct medical costs and direct non-medical costs, indirect costs 
include mortality costs, morbidity costs due to absenteeism and presenteeism, informal 
care costs (in terms of the opportunity cost of hiring outside care) and, for the few 
relevant cases such as substance use or violence, losses due to crime (incarceration, 
policing, legal, and costs to victims of crime). (Ibid.) Summary of direct and indirect 
costs in COI studies are presented in table 2. 
Table 2. Typical items of resource use in COI studies 
Cost type Examples of resources 
Direct medical costs 
Hospitalisation  
• Days of hospitalisation  
• Discharges  
Outpatient visits  
• Outpatient clinic attendance  
• Visit to private practitioner  
• Visit to paramedic  
Procedures and tests  
• Tests (blood analysis, x-ray, scans, gastroscopies, etc)  
• Surgical interventions  
Devices: medical devices (wheelchairs, hearing aid etc)  
Services  
• Home care (hours or days)  
• Nursing care (hours or days)  
Direct non-medical costs  
Transportation  
• For outpatient visits (ambulance, taxi, etc)  
• For daily activities  
Services  
• Home help (hours or days)  
• Meals on wheels  
• Social assistance (hours or days)  
Devices and investments  
• Adaptation to house or car  
• Special kitchen and bathroom utensils  
Informal care: care by relatives 
Indirect costs  
Sick leave (days or weeks)  
Reduced productivity while at work (percentage or hours)  
Early retirement due to illness (years to normal retirement) 
Premature death (years to normal retirement) 
Source: Kobelt (2013) 
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As can be seen, there are a lot of cost sources to be considered in COI studies. The 
specific selection of costs included depends on the perspective of the study and often 
also on data availability. 
Perspective. Scope. Approach 
A cost-of-illness study may be conducted from several different perspectives (see table 
3). Each perspective contains slightly different costs. These perspectives measure costs 
to society, the healthcare system, third-party payers, businesses, the government and 
participants and their families
 
(Luce et al 1996). In COI studies regarding overweight 
and obesity, societal perspective (including direct and indirect costs) and healthcare 
system perspective (including direct medical costs) are most common. The societal 
approach is often favoured because it is the most comprehensive but as a downside, it 
also requires the most data, making it difficult to use in certain cases (especially with 
less common diseases). (Segel 2006) 
Table 3. Costs included in COI studies by perspective 
Perspective Medical costs Morbidity costs Mortality costs Non-medical costs 
Transfer 
payments 
Societal All costs All costs All costs All costs – 
Healthcare 
system All costs – – – – 
Third-party 
payer Covered costs – Covered costs – – 
Businesses Covered costs (self-insured) 
Lost 
productivity 
(presenteeism/ 
absenteeism) 
Lost 
productivity – – 
Government 
Covered 
(Medicare, 
Medicaid) 
– – Criminal justice costs 
Attributable 
to illness 
Participants 
and families 
Out-of-pocket 
costs 
Lost wages/ 
Household 
production 
Lost wages/ 
Household 
production 
Out-of-
pocket costs 
Amount 
received 
Source: Luce et al (1996) 
The scope of COI studies might be broader (incidence based studies) or narrower 
(prevalence based studies). Incidence based studies involve calculating the lifetime 
costs of cases first diagnosed in a particular year, providing a baseline against which 
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new interventions can be evaluated (Byford et al 2000). Incidence costs include the 
discounted medical, morbidity and mortality costs during a person's lifetime for the 
incident cohort. Prevalence based studies on the other hand estimate annual costs and 
measure the costs of an illness in one period (usually a year). Prevalence based studies 
include all medical care costs and morbidity costs for a disease within the study year. 
However, the mortality and permanent disability costs are calculated differently from 
the other costs: they are discounted and calculated for all patients who die or become 
permanently disabled in the study year for that year and each year until the expected age 
of death. (Segel 2006, Hodgson 1988)  
Direct costs in COI studies can be estimated using one of three approaches (Segel 
2006):  
• bottom-up,  
• top-down, 
• the econometric approach.   
Bottom-up studies are based on patient level cost data. They often report excess costs: 
the difference between individual who are affected by a disease and those who are not 
affected. (Lehnert et al 2013) Average cost of treating an illness is multiplied with the 
prevalence of the illness (Segel 2006). 
The top-down approach, also known as the epidemiological or attributable risk 
approach, measures the proportion of a disease that is due to exposure to the disease or 
risk factor (Bloom et al 2001). The approach uses aggregated data along with a 
population attributable fraction (PAF) to calculate the attributable costs (Segel 2006). 
For example: in the case of cost of obesity, top-down COI studies estimate the shares in 
disease-specific costs attributable to overweight/obesity (i.e. population attributable 
fractions or PAFs) by combining data on the prevalence of excess-weight with relative 
risks of developing the specific diseases (Lehnert et al 2013). The formula to calculate 
population attributable fractions is the following:   
(2) !"# = ! !! − 11+ ! !! − 1   
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where: !!" – proportion of medical care for disease B attributable to disease A, ! – prevalence rate of disease A,  !! – unadjusted relative risk of disease B for people with disease A, compared with 
those without disease A. 
The last possible approach is econometric approach. The econometric or incremental 
approach estimates the difference in costs between a cohort of the population with the 
disease and a cohort of the population without the disease. The two cohorts are matched, 
usually via regression analysis, by various demographic characteristics (e.g., sex, age, 
race, geographic location) and the presence of other chronic conditions. (Segel 2006) 
It is important to emphasize the costs of risk factors, such as smoking and obesity, are 
estimated slightly differently than costs of most illnesses. Risk factors have few costs 
themselves but rather cause other illnesses that may have high costs. Thus, the risk 
factor is rarely listed as a diagnosis, meaning many of the surveys of medical care 
utilization for more common illnesses are not appropriate. On the other hand, certain 
risk factors are common, such as smoking and obesity, meaning national databases 
capture the appropriate data. Therefore, a method of attributing the medical costs to the 
risk factor is necessary. Either an econometric or a top-down approach including PAFs 
is used. Thus, the top-down or econometric approaches are more appropriate than the 
bottom-up approach for measuring the costs of a risk factor. (Ibid.) The most common 
COI method for estimating the economic burden of obesity is prevalence based top-
down cost-of-illness method, either from the perspective of the healthcare system or the 
society. In this research paper, the direct medical costs of overweight and obesity are 
also estimated with a prevalence based top-down COI method. In summary, the direct 
medical costs attributable to overweight and obesity will be calculated as follows: 
(3) !"#! = !! ∙ !! ∙ !"#!!!!!!!!!   
where: !"#! – cost of disease ! attributable to overweight and obesity, 
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!! – direct medical cost of disease !, !! – prevalence rate of overweight and obesity among people with disease !, !!"! !– proportion of cost of disease ! attributable to overweight and obesity, 
 ! – number of overweight and obesity related diseases. 
In addition to direct medical costs, indirect productivity costs will also be included, 
giving the analysis a societal perspective. 
Indirect Costs 
Indirect costs include the loss of resources as a result of morbidity and mortality. This 
means valuing life in monetary terms. It often comes with ethical controversy on how to 
accurately calculate the value of life (Cooper and Rice 1976, Hodgson 1983) but also 
creates disagreement on the correct method of estimation (Rice and Hodgson 1982, 
Mrozek and Taylor 2002). To estimate indirect costs, there are three most common 
approaches (Segel 2006): 
• human capital approach (HCA), 
• friction cost approach (FCA), 
• willingness to pay method (WTP). 
The HCA estimates the value of potential lost production from death until retirement 
age, assuming full employment. Alternatively, the FCA assumes someone currently 
unemployed can replace individuals on long-term sick leave after a ‘friction’ period. 
(Liljas 1998) The willingness to pay approach measures the amount an individual would 
pay to reduce the probability of illness or mortality. For practicality reasons, the HCA is 
the most widespread approach used to calculate the indirect costs of an illness. (Segel 
2006) 
In this research paper, morbidity and mortality costs will be estimated in a more 
approximate manner due to lack of available data. In many previous papers (see 
appendix 1), the magnitude of indirect productivity costs of overweight and obesity that 
include both mortality and morbidity are roughly the same as total direct medical costs. 
To get an approximate estimation of indirect costs in this research paper, the author will 
also make an assumption that indirect costs are equal to direct medical costs.  
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Data 
For the empirical part of the study, data for 11 overweight and obesity related diseases 
was used. The selection included diseases most often incorporated in previous cost of 
obesity studies that are most strongly associated with obesity. Data availability also set 
some constraints on choice of diseases. The chosen diseases were divided into 5 
categories:  
• Cancers: 
o cancer of colon, 
o breast cancer, 
o endometrial cancer; 
• Endocrine diseases: 
o type 2 diabetes, 
o hypercholesterolemia; 
• Cardiovascular diseases: 
o hypertension, 
o myocardial infarction, 
o coronary heart disease, 
o stroke; 
• Digestive diseases: gallstones; 
• Musculoskeletal disorders: osteoarthritis. 
Estonian Health Insurance (EHI, in Estonian: Eesti Haigekassa) provided direct medical 
cost data for sum of healthcare services and sum of medication cost (paid by both EHI 
and patients) for these diseases in 2015. The data also includes information about the 
number of patients but it cannot be summarized as one patient might have more than 
one diagnosis. The direct medical cost data is summarized in appendix 2. 
In order to estimate the economic burden of overweight and obesity in Estonia, it was 
first of all necessary to calculate direct medical cost attributable to overweight and 
obesity. For this task population attributable fractions (PAFs) were also needed. To 
calculate PAFs (see again formula 2) relative risk and prevalence data were obtained. 
Relative risk data for chosen 11 diseases was drawn from numerous medical literature 
sources (see notes of table 4) and  – if possible – relative risks were given with lower 
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and upper bounds. The necessary data for prevalence of overweight and obesity among 
patients of a certain disease was unfortunately not available for Estonia, so 
corresponding data was obtained from other studies. For the most part prevalence data 
from European studies was used; there were 2 diseases (colon and endometrial cancer) 
for which such data was unavailable, so in these cases the author used data from US 
studies. After calculating PAFs direct medical cost attributable to overweight and 
obesity for all diseases could be calculated and summarized to obtain total direct cost of 
overweight and obesity in Estonia in 2015. 
Unfortunately there is no appropriate data available to calculate indirect costs of 
overweight and obesity in Estonia. The indirect cost was therefore estimated 
approximately: in relation to direct costs. From previous studies (see appendix 1) it has 
appeared that for the most part indirect costs are roughly of the same size or slightly 
larger than direct medical costs. In this study, the author makes the assumption that 
indirect costs are equal to direct medical costs (i.e. half of total burden of overweight 
and obesity are comprised by indirect costs). 
 
4. Analysis and Results 
As can be seen from table 4, the cost of overweight and obesity in Estonia in 2015 was 
€45,5 million (3,7% of all healthcare expenditures, 0,22% of GDP, €35 per capita). 
Total direct medical cost was €22,8 million, indirect costs were considered to be 
approximately equal to direct medical costs. While 0,22% of GDP might seem a fairly 
modest cost, €45 million would be enough to cover all medical costs of type 2 diabetes 
for 2 years, myocardial infarction for 2,5 years, hypertension for 4 years and breast 
cancer for 4,4 years. Also, €33,9 million – 0,22% of GDP, exactly the cost of over-
weight and obesity in 2015 – was spent on pregnancy and birth benefits in Estonia in 
2008 (Võrk and Karu 2009). Next the direct medical cost of overweight and obesity by 
disease categories is presented. 
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Table 4. Relative risks of chosen obesity related diseases, prevalence of overweight and obesity among patients of these diseases, PAFs, 
total medical cost of diseases and cost of overweight and obesity in Estonia in 2015 
Illness 
Code 
(ICD-
10) 
Overweight and obesity 
Prevalence 
(%) 
Population attributable 
fraction (PAF) 
Total 
medical cost 
of disease 
(€) 
Total medical cost attributable to 
overweight and obesity (€) Relative risk (RR) 
Value Lower bound 
Upper 
bound Value 
Lower 
bound 
Upper 
bound Value 
Lower 
bound 
Upper 
bound 
Cancers   
Cancer of colonad C18 1,30 n.s n.s 74,0% 18,2% 18,2% 18,2% 5 750 961 774 037 774 037 774 037 
Breast cancerae C50 1,15 n.s n.s 52,0% 7,2% 7,2% 7,2% 10 342 242 389 129 389 129 389 129 
Endometrial 
canceraf C55 1,38 n.s n.s 86,5% 24,5% 24,5% 24,5% 5 496 1 164 1 164 1 164 
  Total 16 098 698 1 164 331 1 164 331 1 164 331 
Endocrine 
diseases   
Type 2 diabetesbg E11 2,13 1,30 3,55 79,4% 47,2% 19,2% 66,9% 22 121 949 8 288 817 3 379 821 11 759 668 
Hypercholestero-
lemia (and other 
lipidaemias)bg 
E78 1,35 1,05 1,73 71,3% 20,0% 3,4% 34,1% 2 932 915 417 167 71 897 711 881 
  Total 25 054 865 8 705 984 3 451 718 12 471 549 
Cardiovascular 
diseases   
Hypertensionbg I10 2,10 1,68 2,63 76,6% 45,7% 34,1% 55,5% 11 207 258 3 928 876 2 928 444 4 763 981 
Myocardial 
infarction (acute 
+ subsequent)cg 
I21, I22 3,15 1,58 6,63 65,9% 58,6% 27,7% 78,8% 18 482 347 7 140 673 3 376 776 9 591 375 
Coronary heart 
diseasebh I25 1,05 0,60 1,83 79,0% 3,8% −46,2% 39,5% 7 941 831 238 408 -2 898 536 2 475 623 
Strokeag I64 1,45 n.s n.s 67,6% 23,3% 23,3% 23,3% 14 789 2 330 2 330 2 330 
  Total 37 646 225 11 310 286 3 409 014 16 833 308 
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Table 4 continues 
Illness Code (ICD-10) 
Overweight and obesity 
Prevalence 
(%) 
Population attributable 
fraction (PAF) 
Total 
medical cost 
of disease 
(€) 
Total medical cost attributable to 
overweight and obesity (€) Relative risk (RR) 
Value Lower bound 
Upper 
bound Value 
Lower 
bound 
Upper 
bound Value 
Lower 
bound 
Upper 
bound 
Digestive 
diseases   
Gallstonesai K80 1,88 n.s n.s 72,1% 38,7% 38,7% 38,7% 4 568 241 1 274 338 1 274 338 1 274 338 
Musculoskeletal 
disorders   
Osteoarthritisbj M15 1,35 1,05 1,75 75,0% 20,8% 3,8% 39,6% 2 004 148 312 528 56 367 595 572 
         
Total 
medical 
costs (€) 
22 767 466 9 355 767 32 339 098 
         
Indirect 
productivity 
costs (appr.) 
(€) 
22 767 466 9 355 767 32 339 098 
         TOTAL (€) 45 534 933 18 711 534 64 678 196 
Source: author's calculations 
Notes: 
− Relative risk: a – Mathers et al (1999), b – Kearns et al (2014), c – Oliviera et al (2009) 
− Prevalence: d – Nock et al (2008), e – Rosenberg et al (2009), f – Beavis et al (2015), g – Akin et al (2015), h – De Bacquer et al (2004), i – 
Boland et al (2002), j – Spector et al (1994) 
− Medical cost data from Estonian Health Insurance (Eesti Haigekassa) 
− PAFs calculated according to formula 2 
− Total attributable costs calculated according to formula 3 
− Indirect costs are considered approximately equal to direct costs (based on previous studies) 
− n.s – not specified 
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Cancers 
Total medical cost of cancers was €16,1 million, of which €1,16 million (7,2%) was 
attributable to overweight and obesity. Healthcare services comprised a major part of 
total cost (88%) while medications were only 12% (see appendix 2). This result is 
logical considering the nature of the disease: cancer treatment needs more healthcare 
services (for example chemotherapy) than pharmacy-bought medications. Total medical 
cost of cancers attributable to obesity and overweight comprised 5% of total direct 
medical cost of overweight and obesity, a relatively small proportion. 
Endocrine Diseases 
Total medical cost of endocrine diseases was €25 million, of which €8,7 million (35%) 
was attributable to overweight and obesity. Cost of endocrine diseases (for example 
type 2 diabetes) came mostly from cost of medications (82%), services played a more 
modest role (18%). Total medical cost of endocrine diseases attributable to obesity and 
overweight comprised 38% of total direct medical cost of overweight and obesity, a 
relatively large proportion of total cost. The most costly disease in the whole study was 
type 2 diabetes: €8,3 million. 
Cardiovascular Diseases 
Cardiovascular diseases were the most costly category with €37,6 million, of which 
€11,3 million (30%) was attributable to overweight and obesity. Healthcare services 
comprised ¾ and medications ¼ of total cost. Total medical cost of cardiovascular 
diseases attributable to obesity and overweight comprised the largest proportion – 50% 
– of total direct medical cost of overweight and obesity (see graph 6 for distribution of 
direct medical cost among disease categories). 
Digestive Diseases 
Total medical cost of digestive diseases (gallstones) was €4,6 million, of which €1,3 
million (28%) was attributable to overweight and obesity. As treatment of gallstones is 
surgical, healthcare services comprised 99% and medications only a minor 1% of the 
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cost. Total medical cost of digestive diseases attributable to obesity and overweight 
comprised a modest 5,6% of total direct medical cost of overweight and obesity. 
 
Graph 6. Distribution of direct medical cost of obesity and overweight by disease 
category (author's calculations) 
Musculoskeletal Diseases 
Total medical cost of musculoskeletal disorders (osteoarthritis) was €2 million, of 
which €0,3 million (16%) was attributable to overweight and obesity. Distribution of 
cost among services and medications was almost even (52% and 48%). Total medical 
cost of musculoskeletal disorders attributable to obesity and overweight comprised a 
very small proportion of total direct medical cost of overweight and obesity: only 1,4%. 
Scenario Analysis 
As already mentioned, relative risks of diseases were given with upper and lower 
bounds if possible. Hence, PAFs and total medical cost attributable to overweight and 
obesity were also calculated and given with three values which in the context of this 
study can be named conservative, optimistic (lowest cost possible) and pessimistic 
(highest cost possible) scenario (see table 5).  
50% 
38% 
5,6% 
5% 1,4% 
Cardiovascular diseases 
Endocrine diseases 
Digestive diseases 
Cancers 
Musculoskeletal disorders 
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According to the conservative scenario, the cost of overweight and obesity in Estonia in 
2015 was €45,5 million (3,7% of all healthcare expenditures, 0,22% of GDP, €35 per 
capita). The pessimistic scenario estimates 42% larger cost: €64,7 million (5,2% of all 
healthcare expenditures, 0,32% of GDP, €49 per capita). The optimistic scenario gives 
59% smaller estimate than the conservative scenario: €18,7 million (1,5% of all 
healthcare expenditures, 0,09% of GDP, €14 per capita). It is also worth mentioning that 
according to optimistic scenario, the relative risk of coronary heart disease of 
overweight persons is smaller than risk of normal weight persons (relative risk less than 
1). In medical literature this peculiar phenomenon is known as obesity paradox in 
coronary heart disease (Banack and Kaufman 2014, Lavie et al 2009, Clark et al 2014, 
De Schutter et al 2014). However, it is usually still concluded that weight reduction is 
beneficial for overweight patients with cardiovascular diseases (Lavie et al 2009). The 
obesity paradox is not enough to discourage weight control measures. Obesity paradox 
in CHD still needs further deeper research. 
Table 5. Total cost of overweight and obesity according to conservative, pessimistic 
and optimistic scenario  
Scenario Cost % HE % GDP per capita Change 
Conservative €45,5 million 3,7% 0,22% €35 (baseline) 
Pessimistic €64,7 million 5,2% 0,32% €49 ↑ 42% 
Optimistic €18,7 million 1,5% 0,09% €14 ↓ 59% 
Source: author's calculations 
To test the sensitivity of the results, it was assumed prevalence of overweight and 
obesity among diseases associated with obesity is reduced by 10% (not percentage 
points) for each disease. After this change the total cost of overweight and obesity 
becomes: 
• €38,7 million (−6,8 million, −15%) according to conservative scenario, 
• €55,9 million (−8,8 million, −13,6%) according to pessimistic scenario, 
• €15,9 million (−2,8 million, −14,9%) according to optimistic scenario. 
It appears the results are sensitive to changes in prevalence for all scenarios: a 10% 
decrease in prevalence of overweight reduces cost of overweight and obesity more than 
10% (15%, 13,6% and 14,9% respectively). 
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5. Discussion 
Results  
The cost of overweight and obesity in Estonia in 2015 was €45,5 million (0,22% of 
GDP, 3,7% of healthcare expenditures). The cost is much smaller than in the USA: well 
over 1% of GDP (Wolf and Colditz 1998). As already mentioned, in European countries 
the total cost usually was around 0,5% of GDP. Actually, the cost of overweight and 
obesity in Estonia is more similar to less developed countries like Mexico and Thailand 
than European countries (see graph 7). While the cost of overweight and obesity is not 
yet as large as in other European countries or the USA, it is still a serious warning sign 
from the viewpoint of public health as prevalence of overweight in Estonia has been 
increasing: 58,3% in 2010, 60,3% in 2014 (WHO database). 
 
Graph 7. Total cost (direct medical spending + productivity cost) of (overweight and) 
obesity as a percentage of GDP including Estonia (compiled by the author from 
appendix 1) 
If we look at only direct medical cost of overweight and obesity (€22,8 million, 0,11% 
of GDP, 1,8% of healthcare expenditures), we can observe a similar situation as with 
total cost: 0,11% of GDP puts Estonia among less developed countries (see again graph 
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4). In European countries the direct medical cost was typically 2–4 times larger than in 
Estonia, in Australia up to 6,5 times larger and in USA 7–15 times larger (see graph 8). 
Disease categories with highest direct medical costs were cardiovascular diseases (50% 
of total medical cost of overweight and obesity) and endocrine diseases (38%). The 
most costly diseases were type 2 diabetes (€8,3 million) and myocardial infarction (€7,1 
million).  
 
Graph 8. Direct medical cost of (overweight and) obesity as a percentage of GDP 
including Estonia (compiled by the author from appendix 1) 
Policy Implications 
In addition to well-known health solutions to reduce the burden of overweight: healthy 
eating and recreational sports, promoted for example by WHO (Obesity and 
overweight), in this paper two economic solutions are proposed. 
The first set of solutions is Pigouvian taxes on unhealthy food and drink products, for 
example junk food and refined sugar products like sweets and soft drinks. Such taxes 
are used in some countries around the world. For example, there is a 5,2% sales tax on 
soft drinks in 33 states in the USA (Brownell et al 2009), taxes on refined sugar 
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products of almost 20 NOK (approximately €2) per kilogram in Norway (Sjokolade- og 
sukkervarer) and a tax of 1 peso (€0,05) per litre on soft drinks in Mexico 
(Procuraduria de la Defensa del Contribuyente 2013 via Grogger 2015). Grogger 
(2015) found the soft drink tax in Mexico was relatively powerful: a 9 percent tax 
increased prices of soft drinks by 12 percent. Arantxa Colchero et al (2016) have found 
consumption of soft drinks in Mexico decreased by 6,1% in 2014. However, as Grogger 
(2015) brings out, it is complicated to estimate how the tax affected the body weight of 
Mexicans since the nationwide tax means there are no unaffected consumers to serve as 
controls. We can assume decreased consumption of unhealthy products also decreases 
the body weight but the effect is difficult to quantify. 
Taxation of unhealthy food and drink products has some issues. One problem is taxes 
based on volume only do not direct companies to reduce sugar (or fat) content of their 
products, it only makes them increase the prices. Taxing sugar (or fat) content would 
probably be more effective and encourage businesses to introduce new healthier 
alternatives. (Marron et al 2015) Another issue is that the direct body weight effect of 
such taxes is difficult to estimate (Grogger 2015), making it hard to justify such taxes to 
people, the public, policy makers etc. What is more, the tax of unhealthy food and drink 
products is also regressive, affecting lower income population relatively more (Marron 
et al 2015). A Pigouvian tax on unhealthy foods and drinks should be implemented 
alongside health education to direct people towards healthier dietary choices. 
The second set of solutions is taxes based on body weight. These taxes have not yet 
been implemented or evaluated anywhere. One option would be to tax all excessive 
units of weight (for example kilograms) of an overweight person. This option has been 
previously very briefly mentioned by Võrk (2012). The second option would be a tax 
reduction (for example social tax) for all normal weight people. The third option would 
be an increase in cost-sharing of healthcare services for overweight people. A tax 
should create incentives for overweight population to lose their excessive weight and 
also extra revenue for government budget. However, there are numerous issues with 
solutions including a tax of such nature.  
Firstly, it would be problematic to identify the people who should be taxed in case of an 
excessive weight tax. Self-reporting would fail because most overweight people would 
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simply report false data in order to avoid the tax. Compulsory weight and height 
measuring by family doctors would create a huge extra workload for the doctors. In case 
of a tax reduction for normal weight people, issues related to weight reporting would be 
less prevalent because people themselves would be interested in the tax reduction. 
Therefore they would be more eager to report their weight and height (for example in 
special facilities) to avoid the tax in legal ways.  
Secondly, defining overweight via BMI might be unfair in some cases. For example, 
some athletes who have higher than normal lean muscle mass and therefore more body 
weight (bodybuilders, weight-lifters, discus throwers, shot-putters etc) and most 
pregnant women would be considered overweight when in reality they are perfectly 
healthy and should not be subject to tax. The list of exceptions would have to be 
thorough and all-encompassing. 
Thirdly, the size of the tax would have to be very carefully calculated. In case of an 
excessive weight tax, it should be considered whether the tax needs to be progressive, 
i.e. should all excessive weight units be taxed equally or differently in different 
overweight and obesity classes. For example, the tax on an excessive kilogram of an 
overweight person (25 ≤ BMI < 30) should probably bear a smaller tax than for the 
morbidly obese (BMI ≥ 40) person because the risks of obesity-related diseases are 
significantly larger for the morbidly obese than for the modestly overweight people. In 
case of a tax reduction for normal weight people, the tax reduction should be 
proportional but the size of the reduction would still need profound determination.  
What is more, as overweight and obesity in developed countries are more prevalent 
among poorer population (Sobal and Stunkard 1989, McLaren 2007), the tax solution 
would be regressive from the perspective of social policy (Võrk 2012). Whether it is a 
desirable result for the society, is somewhat unlikely. It is also questionable whether a 
tax based on such personal data like weight is ethical or not. Another aspect to consider 
is the fact that simultaneously to tax implementation, people should also be educated on 
healthy eating and sports as measures to get rid of excessive body weight. A tax is not 
meant to simply be a punishment for being overweight but rather be an incentive to lose 
weight and therefore reduce health risks related to overweight. 
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Lastly, body weight based tax solutions need thorough cost-benefit analysis before 
implementation. It is possible costs associated with implementation of the tax are larger 
than the benefit achieved, therefore making the tax economically unreasonable. In 
conclusion, there are many issues to be considered with body weight based taxes but if 
done properly, they could reduce the prevalence and the economic burden of overweight 
and obesity. To sum up, tax solutions are an imperfect solution but can have a moderate 
positive effect if done correctly. 
Limitations 
There are some limitations of the study to be considered. The first set of limitations is 
related to the cost-of-illness method. Firstly, COI studies demonstrate which diseases 
need more resources for treatment or prevention but fail to determine how resources 
should be allocated since they do not include benefits. Therefore, cost-benefit or cost-
effectiveness analysis would provide valuable extra information. (Segel 2006, Roux and 
Donaldson 2004) Secondly, COI studies can differ by inclusion of indirect costs, 
perspective, data sources, time frame (Hodgson and Meiners 1982) and diseases (Kortt 
et al 1998), making it difficult to compare the results of different studies. Also, 
exclusion of some diseases would underestimate the overall economic burden of obesity. 
Thirdly, prevalence based COI studies do not quantify the long-term consequences of 
chronic conditions such as obesity. (Kortt et al 1998) What is more, many diseases are 
considerably intertwined but the costs are counted for separately. Therefore, there is a 
threat of double-counting and overestimation (Roux and Donaldson 2004, Bierl et al 
2013). Still, COI studies are an important analytic tool for public health policy if 
presented with clear explanations (Segel 2006). 
Another possible set of limitations is imperfect data. There was no prevalence data of 
overweight and obesity among patients of chosen diseases available for Estonia, so 
mostly data from other European countries and in some cases USA had to be used. This 
limitation can probably create some difference from the actual cost, although we can 
assume it is not too large since prevalence of overweight and obesity in Europe is pretty 
similar across countries (see graph 1), so we can assume prevalence among chosen 
diseases is also similar. In addition to prevalence data, there was no appropriate data to 
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calculate indirect costs of overweight and obesity, so approximate estimation based on 
direct medical costs had to be used.  
There is reason to believe the cost of overweight and obesity in this research might 
actually be conservative. The direct medical cost of overweight and obesity is based on 
money spent on healthcare services and medications. However, if the healthcare budget 
is small, the cost of obesity will also be small. The overall medical expenditures are 
much lower in Estonia, a small post-Soviet eastern European country, than in more 
developed European countries like Sweden and Germany (6,2%, 9,7% and 11,3% of 
GDP respectively, see appendix 3), so in theory the cost of obesity could be greater but 
Estonia does not spend as much money as the healthcare sector actually needs, making 
the cost of overweight and obesity artificially smaller. Also, there is a higher risk of 30 
diseases associated with overweight and obesity (see illustration 1) but due to data 
availability only 11 most important diseases were included in this study. Had all 
diseases been included, the cost of obesity would have been larger. What is more, not 
all types of cost related to overweight and obesity (for example direct non-medical 
costs) were possible to include in this study, further increasing the probability of 
underestimation (Lal et al 2012). 
Further Research 
Future directions for research include using improved data, specifically prevalence data 
from Estonia instead of other similar European countries, to get a more precise picture 
of the burden of overweight and obesity in Estonia, and as a next step conducting cost-
effectiveness or cost-benefit analyses for provided tax solutions (Pigouvian taxation of 
unhealthy food and drink products or body weight based taxes) to see if and how much 
they would help to alleviate the problem in Estonia.  
 
6. Conclusion and Acknowledgements  
Overweight and obesity is a fast-spreading global problem that has gotten more and 
more attention in the last couple of decades. It is a more severe problem in developed 
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countries although prevalence of overweight and obesity is growing also in the 
developing world. This has sparked interest among researchers to somehow quantify the 
cost of excessive body weight on societies. Most studies have been conducted for the 
USA or Europe, although there are some available for less developed countries as well. 
In this research paper, the cost of overweight and obesity in Estonia was studied with 
prevalence based top-down cost-of-illness method and Estonian Health Insurance cost 
data for healthcare services and medications of 11 diseases associated with excess body 
weight. 
In 2015 the total cost of overweight and obesity in Estonia was €45,5 million (0,22% of 
GDP, 3,7% of healthcare expenditures, €35 per capita). In the USA such cost has 
usually been around 1% of GDP and in Europe around 0,5% of GDP. It appears the 
total cost of overweight and obesity in Estonia – a small post-Soviet eastern European 
country with relatively poor health indicators and relatively low healthcare expenditures 
– is more comparable to less developed countries (Thailand, Mexico) than the western 
world.  
The cost of overweight and obesity is comprised of direct medical costs and indirect 
productivity costs. Indirect costs were estimated approximately based on direct costs 
due to lack of data. Direct cost was €22,8 million (0,11% of GDP, 1,8% of healthcare 
expenditure) which again is significantly (2–4 times) higher in Europe and up to 15 
times higher in the USA, reaching up to 1,6% of GDP according to some studies. The 
most costly diseases were type 2 diabetes (€8,3 million) and myocardial infarction (€7,1 
million), both strongly associated with obesity.  
From these results it seems overweight and obesity is not yet as large of a problem as in 
other developed countries. However, the increasing prevalence of overweight, obesity 
and associated diseases give reason to doubt the cost will remain moderate. Perhaps it is 
more useful to learn from experience of other countries and make effort to eradicate or 
reduce overweight and obesity with lower cost than wait for the problem to deepen 
further and cope with it later. In addition to promoting healthy eating and recreational 
sports, Pigouvian taxation of unhealthy food and drink products and body weight based 
taxes could be an incentive to make changes towards a healthier lifestyle, therefore 
reducing the burden on the society. 
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Appendices  
Appendix 1. Summary of empirical cost of (overweight and) obesity studies (compiled by the author) 
Authors Country Year BMI criteria 
Medical Conditions /  
Variables included 
Cost 
components Method 
Cost of obesity 
Abs. 
values 
% of health 
expend. % of GDP 
Segal et al 
(1994) Australia 1990 BMI ≥ 30 
• Type 2 diabetes 
• CHD 
• Gallstones 
• Cancers: 
o Colon 
o Breast (postmenopausal) 
• Weight-control efforts 
Direct 
medical costs COI 
$AU400 
million 2% ≈0% 
Colagiuri et 
al (2010) Australia 2005 BMI ≥ 30 
Total medical expenditures (using 
comparison group) 
Direct 
medical costs COI 
$AU8,3 
billion 7,6% 0,65% 
Anis et al 
(2010) Canada 2006 BMI ≥ 25 
• Type 2 diabetes 
• Cardiovascular diseases: 
o Coronary artery disease 
o Hypertension 
o Congestive heart failure 
o Stroke 
o Pulmonary embolism 
• Osteoarthritis 
• Gallbladder disease 
• Asthma 
• Chronic back pain 
• Cancers: 
o Breast (postmenopausal) 
o Colon 
o Endometrial 
o Oesophageal 
o Kidney 
[continues on next page…] 
Direct 
medical costs COI 
$C6 
billion 4,1% 0,4% 
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Appendix 1 continues 
Authors Country Year BMI criteria 
Medical Conditions /  
Variables included 
Cost 
components Method 
Cost of obesity 
Abs. 
values 
% of health 
expend. % of GDP 
    
o Ovarian 
o Pancreatic 
o Prostate 
     
Human capital costs: morbidity 
included, mortality excluded 
Productivity 
costs HCA 
$C5 
billion  0,33% 
Janssen 
(2013) Canada 2006 BMI ≥ 30 
• Endocrine and metabolic disorders 
o Type 2 diabetes 
o Gallbladder disease 
• Cancer  
o Colorectal 
o Pancreatic 
• Cardiovascular disease  
o Coronary artery disease 
o Stroke 
• Lung disease  
o Asthma 
o Pulmonary embolism 
• Musculoskeletal disorders 
o Osteoarthritis 
o Chronic back pain 
• Mental health disorders  
o Depression 
o Dementia 
Direct medical 
costs 
COI 
$C3,9 
billion 2,7% 0,26% 
Costs related to disability and lost 
productivity due to illness or 
premature death 
Productivity 
costs 
$C3,2 
billion  0,21% 
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Appendix 1 continues 
Authors Country Year BMI criteria 
Medical Conditions /  
Variables included 
Cost 
components Method 
Cost of obesity 
Abs. 
values 
% of health 
expend. % of GDP 
Zhao et al 
(2007) China 2003 BMI ≥ 24 
• Hypertension 
• Type 2 diabetes 
• Coronary heart disease 
• Stroke  
Direct medical 
costs COI 
$2,74 
billion 3,7% 0,18% 
Levy et al 
(1995) France 1992 BMI ≥ 27 
• Hypertension  
• Myocardial infarction 
• Angina pectoris  
• Stroke  
• Venous thrombosis  
• Type 2 diabetes 
• Hyperlipidaemia  
• Gout 
• Osteoarthritis  
• Gall bladder disease  
• Cancers: 
o Colon 
o Breast 
o Genitourinary  
• Hip fracture  
• Direct 
medical 
costs 
 
• Productivity 
costs 
COI FF12,5 billion 2% 0,28% 
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Appendix 1 continues 
Authors Country Year BMI criteria 
Medical Conditions /  
Variables included 
Cost 
components Method 
Cost of obesity 
Abs. 
values 
% of health 
expend. % of GDP 
Konnopka 
et al 
(2011) 
Germany 2002 BMI ≥ 25 
• Cancers: 
o Oesophagus 
o !Stomach 
o Colon 
o Liver 
o !Gallbladder 
o !Pancreas 
o Postmenopausal breast 
o Cervix uteri 
o Ovary 
o !Prostate 
o !Kidney 
o Non-Hodgkin’s lymphoma 
o Multiple myeloma 
o Leukemia 
• Endocrine diseases: 
o Type 2 diabetes 
o Adiposity 
o Hyperlipidaemia  
• Cardiovascular diseases 
o Hypertension 
o !Coronary heart disease  
• Digestive diseases  
o Gallbladder disease 
Direct 
medical costs COI 
€4,9 
billion 2,1% 0,22% 
• Sickness absence 
• Early retirement  
• Early mortality  
Productivity 
costs HCA 
€5 
billion  0,23% 
 42 
Appendix 1 continues 
Authors Country Year BMI criteria 
Medical Conditions /  
Variables included 
Cost 
components Method 
Cost of obesity 
Abs. 
values 
% of health 
expend. % of GDP 
Sansores 
and 
Gutierrez-
Delgado 
(2015) 
Mexico 2013 BMI ≥ 25 
• Diabetes 
• Cardiovascular disorders 
• Osteoarthritis 
• Cancers: 
o Esophagus 
o Pancreas 
o Breast 
o Cervix 
o Colon 
Direct 
medical 
costs 
COI ≈$1,2 billion 17% 0,1% 
• Lost income from premature death 
• Temporary disability subsidies 
• Permanent disability pension 
• Opportunity cost for the non-
medical care giver 
Productivity 
costs HCA 
≈$2,4 
billion  0,2% 
Seidell 
and 
Deeren-
berg 
(1994) 
Nether-
lands 1990 BMI ≥ 30 [not specified] 
Direct 
medical 
costs 
COI DG1 billion 4% 0,35% 
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Appendix 1 continues 
Authors Country Year BMI criteria 
Medical Conditions /  
Variables included 
Cost 
components 
Metho
d 
Cost of obesity 
Abs. 
values 
% of health 
expend. % of GDP 
Swinburn 
et al 
(1997) 
New 
Zealand 1991 BMI ≥ 30 
• Type 2 diabetes 
• CHD 
• Hypertension 
• Cancers: 
o Breast (postmenopausal) 
o Colon 
Direct 
medical 
costs 
COI $NZ135 million 2,5% 0,3% 
Lal et al 
(2012) 
New 
Zealand 2006 BMI ≥ 25 
• Type 2 diabetes 
• Stroke 
• CHD 
• Hypertension 
• Osteoarthritis 
• Cancers: 
o Breast 
o Colon 
o Endometrial 
o Kidney 
Direct 
medical 
costs 
COI $NZ624 million 4,4% 0,38% 
All of the above and: 
• Productivity losses HCA:  
o Premature deaths  
o Short-term absenteeism costs  
• OR 
• Productivity losses FCA:  
o Premature deaths  
o Recruitment and Training costs  
o Short-term absenteeism costs  
• Direct 
medical 
costs 
 
• Productivity 
costs 
COI 
 
HCA 
or 
FCA 
$NZ722–
849 
million 
5,1%–6% 0,44%–0,52% 
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Appendix 1 continues 
Authors Country Year BMI criteria 
Medical Conditions /  
Variables included 
Cost 
components Method 
Cost of obesity 
Abs. values % of health expend. % of GDP 
Krysanova 
and 
Žuravleva 
(2015) 
Russia 2013 (?) BMI ≥ 25 
• Stroke 
• Heart attack 
• Type 2 diabetes 
Direct 
medical 
costs 
COI 
364 billion 
rubles 
($6,8 
billion) 
5% 0,33% 
Borg et al 
(2005) Sweden 2002 BMI ≥ 25 
Total medical expenditure of obese 
or overweight compared to normal 
weight group 
Direct 
medical 
costs Regress.analysis 
$269 
million 2,3% 0,21% 
Cost due to premature mortality Productivity costs 
$367 
million  0,29% 
Pitaya-
tienanan 
et al 
(2014) 
Thailand 2009 BMI ≥ 25 
• Cancers: 
o Colon 
o Breast  
o Endometrial 
• Hyperlipidemia 
• Type 2 diabetes  
• Depression 
• Hypertension 
• CHD 
• Pulmonary embolism 
• Stroke 
• Gall bladder disease 
• Osteoarthritis 
Direct 
medical 
costs 
COI 
THB5,6 
billion 
($333 
million) 
1,5% 0,06% 
• Absenteeism 
• Premature mortality 
Productivity 
costs HCA 
THB6,6 
billion 
($392 
million) 
 0,07% 
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Appendix 1 continues 
Authors Country Year BMI criteria 
Medical Conditions /  
• Variables included 
Cost 
components Method 
Cost of obesity 
Abs. 
values 
% of 
health 
expend. 
% of GDP 
House of 
Commons 
Health 
Commit-
tee (2004) 
UK 2002 BMI ≥ 30 
• Type 2 diabetes 
• Hypertension  
• Angina pectoris  
• Myocardial infarction 
• Cancers: 
o Endometrial 
o Colon  
o Rectal  
o Ovarian  
o Prostate  
• Osteoarthritis  
• Gout  
• Stroke 
• Gallstones  
Direct 
medical 
costs 
COI 
£990–
1220 
million 
2,3%–
2,6% 
0,17%–
0,2% 
Ellison et 
al (2015) UK 2015 BMI ≥ 25 [not specified] 
Direct 
medical 
costs 
[not 
specified] 
£5 
billion 4,3% 0,4% 
Colditz 
(1992) USA 1986 
BMI ≥ 
27,8 
for men 
 
BMI ≥ 
27,3 for 
women 
• Type 2 diabetes 
• Cardiovascular disease 
• Gallbladder disease 
• Hypertension 
• Cancers: 
o Breast 
o Endometrial 
o Colon 
• Direct 
medical 
costs 
• Productivity 
costs 
COI $39 billion 5,5% 0,49% 
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Appendix 1 continues 
Authors Country Year BMI criteria 
Medical Conditions /  
Variables included 
Cost 
components Method 
Cost of obesity 
Abs. 
values 
% of 
health 
expend. 
% of GDP 
Wolf and 
Colditz 
(1998) 
USA 1995 BMI ≥ 29 
• Type 2 diabetes 
• Cardiovascular disease 
• Gallbladder disease 
• Hypertension 
• Cancers: 
o Breast 
o Endometrial 
o Colon 
• Musculoskeletal disease 
Direct medical 
costs 
COI 
$52 
billion 5,7% 0,75% 
All of the above + productivity 
costs (morbidity & mortality) 
• Direct medical 
costs 
• Productivity 
costs 
$99 
billion 10,9% 1,44% 
Finkel-
stein et al 
(2003) 
USA 1998 BMI ≥ 25 Total medical expenditures grouped by insurance category 
Direct medical 
costs 
4-
equation 
regression 
$78 
billion 9,1% 1,26% 
Finkel-
stein et al 
(2009) 
USA 2008 BMI ≥ 30 Total medical expenditures grouped by insurance category 
Direct medical 
costs 
4-
equation 
regression 
$147 
billion 10% 1,13% 
Cawley 
and 
Meyer-
hoefer 
(2012) 
USA 2008 BMI ≥ 30 • Total medical expenditures 
• 3rd party medical expenditures  
Direct medical 
costs IV 
$210 
billion 20,6% 1,61% 
Notes: COI – cost-of-illness method, HCA – human capital approach, IV – instrumental variable approach 
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Appendix 2. Direct medical cost data for chosen obesity-related diseases 
Illness Code (ICD-10) 
Services Medications Total medical 
cost (€) No of patients Sum of services (€) 
No of 
patients 
Paid by 
EHI (€) 
Paid by 
patients (€) 
Total (EHI + 
patients) (€) 
Cancers   
Cancer of colon C18 2 207 4 954 419 1 197 765 147 31 394 796 541 5 750 961 
Breast cancer C50 5 649 9 248 583 3 847 1 022 805 70 855 1 093 659 10 342 242 
Endometrial cancer C55 13 5 492 1 0 3 4 5 496 
  Total 14 208 494   1 787 952 102 252 1 890 204 16 098 698 
Endocrine diseases   
Type 2 diabetes E11 45 507 4 200 845 60 642 15 444 006 2 477 098 17 921 105 22 121 949 
Hypercholesterolemia 
(and other lipidaemias) E78 27 037 319 392 65 113 1 255 453 1 358 071 2 613 524 2 932 915 
  Total 4 520 236   16 699 459 3 835 169 20 534 628 25 054 865 
Cardiovascular 
diseases   
Hypertension I10 106 214 2 515 196 131 503 4 699 454 3 992 609 8 692 062 11 207 258 
Myocardial infarction 
(acute + subsequent) I21, I22 3 677 18 359 033 2 341 59 292 64 022 123 314 18 482 347 
Coronary heart disease I25 15 328 7 336 135 12 241 294 732 310 964 605 696 7 941 831 
Stroke I64 93 14 349 11 165 276 441 14 789 
  Total 28 224 712   5 053 642 4 367 870 9 421 513 37 646 225 
Digestive diseases   
Gallstones K80 8 063 4 523 477 1 847 17 141 27 623 44 764 4 568 241 
Musculoskeletal 
disorders   
Osteoarthritis M15 20 370 959 834 29 645 398 955 645 358 1 044 313 2 004 148 
  TOTAL (€) 52 436 754   23 957 150 8 978 273 32 935 423 85 372 176 
Source: Estonian Health Insurance 
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Appendix 3. Total expenditures on health as a percentage of GDP 
  
Source: WHO database
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